Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 4/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29863061 | 1.00 | KRAS (0.33) | KRASSOS1 | |
| SCHEMBL24800366 | 0.79 | ALDH1A1 (0.35) | — | |
| SCHEMBL30754558 | 0.79 | TOP1 (0.32) | KRASSOS1 | |
| SCHEMBL27093848 | 0.79 | TOP1 (0.32) | KRASSOS1 | |
| SCHEMBL29882037 | 0.79 | ADORA1 (0.36) | KRASSOS1 | |
| SCHEMBL29926474 | 0.76 | KRAS (0.48) | KRASSOS1 | |
| SCHEMBL21494905 | 0.76 | KRAS (0.48) | KRASSOS1 | |
| SCHEMBL21494871 | 0.73 | KRAS (0.52) | KRASSOS1 | |
| SCHEMBL29926561 | 0.73 | KRAS (0.52) | KRASSOS1 | |
| SCHEMBL30878232 | 0.73 | PIK3CD (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024056782-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-21 | — | — | WO | disclosed |
| US-20230029385-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER AG (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230029385-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER AG (DE) | 2023-01-26 | — | — | US | disclosed |
| CN-115315424-A | 2-methyl-aza-quinazolines | 拜耳公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-115028644-A | SOS1 inhibitor heterocyclic compounds | 首药控股(北京)股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-20220274979-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-09-01 | — | — | US | disclosed |
| EP-4045505-A1 | 2-METHYL-AZA-QUINAZOLINES | Bayer Aktiengesellschaft (DE) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021074227-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-22 | — | — | WO | disclosed |
| EP-3781565-A1 | 2-METHYL-AZA-QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019201848-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201848-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029385-A1 | 2-METHYL-AZA-QUINAZOLINES | AZI2, DNMT1, TPMT | KRAS 145/4885SOS1 2630/4885 |
| US-20220274979-A1 | 2-METHYL-AZA-QUINAZOLINES | AZI2, DNMT1, TPMT | KRAS 116/4885SOS1 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.